eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 32

Diagnostic and therapeutic difficulties in hypogammaglobulinemia in adults

Jerzy Świerkot
Arkadiusz Chlebicki
Aleksandra Lewandowicz-Uszyńska
Magdalena Szmyrka-Kaczmarek
Adam Jankowski
Jacek Szechiński

(Centr Eur J Immunol 2007; 32 (1): 11-14)
Online publish date: 2007/04/16
Article file
- Diagnostic.pdf  [0.06 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Patients with rheumatic diseases have various abnormalities in immune system. One of these is hypogammaglobulinemia, that can be caused by different factors (table 1). We aim at present patient cases with rheumatologic diseases with coexistent hypogammaglobulinemia.

Case 1: Hypogammaglobulinemia after treatment with gold salts
Fifty year old woman with rheumatoid arthritis diagnosed 5 years earlier was treated with sulfasalazine,
D-penicilamine and glucocorticosteroids (prednisolon
5-7,5 mg/day). Because of high disease activity gold salts were started (injectable form – disodium aurothiomalate) which were continued for 18 months. Cumulative dose of gold salts was 1500 mg. Initially the therapy was well tolerated. After 5 months 50% improvement according to ACR was reached, which was sustained till the cessation of treatment. During the last 3 months of therapy patient had several infections of upper respiratory tract. Diagnostic tests showed gradual decrease of serum immunoglobulin levels, especially IgG, what was the reason why gold salts were stopped (table 2). Following treatment consisted of leflunomid. Four months later control serum tests were made, which showed the increase of immunoglobulin levels and there was no need for substitute therapy with IVIG.

Case 2: CVID and spondyloarthropathy
47year old woman was admitted to rheumatologic department because of ankle joints arthritis. She had a history of recurrent angina and bilateral uveitis. She had increased ESR (24 mm Hg) and positive test for chlamydia trachomatis from urethra and eye swab. She was diagnosed with reactive arthritis and treated with doxycycline and sulfasalazine. Treatment brought about partial improvement in arthritis, but 7 months later she was admitted again with polyarthritis and psoriatic skin changes. Chlamydia trachomatis was then negative. There was limited mobility of the spine. She was continuously treated with sulfasalasine and NSAID for 2 years.
At the age of 51 she was admitted again because of acute polyarthritis and fever to 39°C and swelling and erythema of eyelids. Laboratory evaluation showed an ESR of 76 mm Hg, CRP – 4,7 mg%, WBC 5900/mm3 (13% lymphocytes). Lymphocyte T count was 284 and lymphocyte B – 138. HIV infection was excluded. Serum protein electrophoresis showed normal total protein level but only 6.4% gammaglobulin and decreased level of IgG, IgA and IgM.
IgG level was 393 mg%, IgA 33 mg% and IgM 36 mg%. There was neither rheumatoid factor nor ANA antibodies. Complement level was 128 UI/ml (N;66-146). In lymphocyte T test there was 20% T1 – early lymphocytes and 37% T2-late lymphocytes. Fluorescence method showed 18% B lymphocytes.
Blood and urine cultures were sterile. She was treated with amoxicilline – clavulonic acid, biodacine and with IVIG which caused disappearance of fever and remission of clinical symptoms. She was diagnosed with spondyloarthropathy and CVID. For the next 6 months she was treated with six doses IVIG. Control blood tests showed normal levels of inflammatory parameters, control test for Chlamydia trachomatis was negative. Clinically there persisted mild arthralgia and swelling of PIP and left ankle joint. There were no active psoriatic skin lesions. Because of recurrent anterior uveitis she was treated with local steroids.


Case 1.

Many disease-modifying antirheumatic drugs, including gold, D-penicillamine, sulfasalazine, azathioprine, and cyclophosphamide, cause symptomatic hypogammaglobulinemia in some patients [1]. The exact mode of gold action in rheumatoid arthritis is unknown. Gold compounds alters macrophage and complement functions. Therapeutic effects include: inhibition of signal transduction, NF kappa B activation, inhibition of B cell activation, increase of
IL-1ra production. About 40% of patients experience some toxicity. The most common reaction is dermatitis and proteinuria. Hematologic abnormalities occur in 1-2 % of patients – the most common is thrombocytopenia and leucopenia. When hematological adverse reactions occur gold should not be restarted. Parenteral gold was first associated with a significant decrease in serum gammaglobulin levels in 1973 by Strong et al. [2]. Hypogammaglobulinemia usually occurs in the first few months of therapy, affects patients of any age and has been associated in the majority of cases with recurrent bacterial infections.
The following mechanisms are considered:
• direct effect of gold on the humoral compartment of immunity [3],
• dysfunction of the regulatory monocyte-macrophage system [4],
• partial blockade of B-cell maturation at the early pre-B stage, with no apparent interference of serum factors [5].

In some cases hypogammaglobulinemia disappears after the treatment is stopped, in other substitute IVIG are needed. Other drugs which can potentially cause drug-induced hypogammaglobulinemia are sulfasalazine, D-penicillamine, azathioprine or cyclophosphamide. Hypogammaglobulinemia during treatment with DMARD is not prompting to stop this unless there are recurrent infections. The same holds true for IVIG treatment. These patients should however be closely monitored.

Case 2.

Reiter’s syndrome, psoriatic arthritis, and the related spondyloarhropathies, have been reported to occur at greater than expected prevalence among HIV-positive individuals.
There are however only single case reports on coincidence of primary hypogammaglobulinemia, including CVID and spondyloatrhropathy.
Common variable immunodeficiency is a group of syndromes characterized by defective antibody formation and decreased serum antibody concentrations in at least two immunoglobuline isotypes. CVID has different course, that is why there are so many theories about its etiology, family and genetic factors predisposing to the disease. The diagnosis is made upon exclusion of other cause of humoral immune defects. CVID affects both genders equally, and often presents in young adulthood. Patients have recurrent bacterial infections, most often of the upper and lower respiratory tracts.
Among the 103 CVID patients observed by Cunningham -Rundles 22% had simultaneously autoimmune disorders. Before diagnosis of CVID two of them had colitis (in one case autoimmune colitis, in other ulcerative colitis). In one patient sacroilitis was found [6]. Ardenis et al describe a patient with CVID and arthritis due to Chlamydia pneumoniae. The patient had a history of recurrent respiratory tract infections, and the latest exacerbation was followed by arthritis. Chlamydia pneumoniae was detected in synovial fluid specimens by cell culture technique. Her nasopharyngeal swab and sputum culture specimens were also positive for this pathogen. Chlamydia pneumoniae should be kept in mind as a causative pathogen in patients with CVID and arthritis [7]. Patients with selective IgA deficiency are prone to developing seronegative spondylarthropathies, including ankylosing spondylitis [8]. Several patients have coexistent ankylosing spondyloarthropathy and symptomatic IgA deficiency [9]. In differential diagnostic in the case of our patient one should consider the decrease of immunoglobulin levels as a result of sulfasalazine treatment. Unfortunately immunoglobulin levels were not checked before the first administration of sulfasalazine.
It should be emphasized that joint pain and arthritis present in the course of CVID are not especially responsive to DMARD treatment but disappear after treatment with intravenous immunoglobulins. This was also the case in our patient.


1. In diagnostics of patients with recurrent infections, especially bacterial, and joint pain one should always consider immune deficiencies.
2. In differential diagnostics of hypogammaglobulinemia one should consider secondary causes of decreased immunoglobulin levels:
• medication,
• autoimmune disorders,
• neoplasms,
• infections,
• states with protein loss [10].


1. Lee AH, Levinson AI, Schumacher HR Jr (1993): Hypogammaglobulinemia and rheumatic disease. Semin Arthritis Rheum 22: 252-264.
2. Strong JS, Bartholomew BA, Smyth CJ (1973): Immunoresponsiveness of patients with rheumatoid arthritis receiving cyclophosphamide or gold salts. Ann Rheum Dis 32: 233-237.
3. Stuckey BG, Hanrahan PS, Zilko PJ, et al. (1986): Hypogammaglobulinemia and lung infiltrates after gold therapy. J Rheumatol 13: 468-469.
4. So AK, Peskett SA, Webster AD (1984): Hypogammaglobulinaemia associated with gold therapy. Ann Rheum Dis
43: 581-582.
5. Guillemin F, Bene MC, Aussedat R, et al. (1987): Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells. J Rheumatol 14: 1034-1035.
6. Cunningham-Rundles C (1989): Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 9: 22-33.
7. Ardeniz O, Gulbahar O, Mete N, et al. (2005): Chlamydia pneumoniae arthritis in a patient with common variable immunodeficiency. Ann Allergy Asthma Immunol 94: 504-508.
8. Pipitone N, Fioravanti A, Marcolongo R, et al. (2001): Articular involvement in the course of primary hypogammaglobulinemia. Recenti Prog Med 92: 63-67.
9. Herrero-Beaumont G, Armas JB, Elswood J, et al. (1990): Selective IgA deficiency and spondyloarthropathy: a distinct disease? Ann Rheum Dis 49: 636-637.
10. Swierkot J, Lewandowicz-Uszynska A, Jankowski A, et al. (2005): The arthritic pathologies accompanying primary immunodeficiencies with antibody synthesis disturbances. Postepy Hig Med Dosw (Online) 59: 219-223.
Copyright: © 2007 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.